Adhesive damping systems are described. A damping system for reducing the effects on a substrate caused by a disruption in the substrate environment includes an adhesive having a plurality of three-dimensional nanoparticles dispersed therein. The nanoparticles are configured to provide a controlled response to an applied force field. The system further includes a sensor which measures an amplitude and frequency spectrum of the disruption. In a use configuration, the sensor determines the amplitude and frequency spectrum of the disruption received by the substrate; and the applied force field is dependent on the amplitude and frequency spectrum of the disruption.

Adhesive damping systems are described. A damping system for reducing the effects on a substrate caused by a disruption in the substrate environment includes an adhesive having a plurality of three-dimensional particles dispersed therein. The particles are configured to provide a controlled response to an applied force field. The system further includes a sensor which measures an amplitude and frequency spectrum of the disruption. In a use configuration, the sensor determines the amplitude and frequency spectrum of the disruption received by the substrate; and the applied force field is dependent on the amplitude and frequency spectrum of the disruption.

A nanoglue is formed with one or more bioadhesive polymers, one or more dendrimers, and optionally one or more therapeutic, prophylactic, or diagnostic agents. The bioadhesive polymers and dendrimers are modified with functional groups to permit crosslinking upon one or more stimuli, e.g., ultraviolet irradiation, and form hydrogel in situ at tissue sites. In the repair of corneal wounds, the nanoglue leads to improved rate of healing with less scarring and less inflammation, compared to non-treated cornea or ones treated with sutures. Therapeutic agents can be covalently conjugated to the precursor components and be delivered to specific eye compartments, providing a more efficacious treatment formulation of ocular disorders than delivering drugs in their free forms. Methods of making and using the hydrogel and hydrogel precursor compositions are also provided.

A nanoglue is formed with one or more bioadhesive polymers, one or more dendrimers, and optionally one or more therapeutic, prophylactic, or diagnostic agents. The bioadhesive polymers and dendrimers are modified with functional groups to permit crosslinking upon one or more stimuli, e.g., ultraviolet irradiation, and form hydrogel in situ at tissue sites. In the repair of corneal wounds, the nanoglue leads to improved rate of healing with less scarring and less inflammation, compared to non-treated cornea or ones treated with sutures. Therapeutic agents can be covalently conjugated to the precursor components and be delivered to specific eye compartments, providing a more efficacious treatment formulation of ocular disorders than delivering drugs in their free forms. Methods of making and using the hydrogel and hydrogel precursor compositions are also provided.

According to the present disclosure, a bioadhesive formulation is provided. The bioadhesive formulation comprises a polycaprolactone dendrimer having a dendrimer core and a plurality of polycaprolactone chains extending from the dendrimer core, wherein at least one of the polycaprolactone chains has an end which is covalently attached with a diazirine, and wherein the diazirine converts to a carbene or a diazoalkyl when a stimulant is applied to the bioadhesive formulation. Methods of forming the bioadhesive formulation are also provided. The bioadhesive could be used in (i) the prevention of thrombosis from tissue fixation and/or (ii) the relief of discomfort and/or pain during and/or after surgery. Preferably, the bioadhesive formulation further comprises a hygroscopic additive, an antithrombotic agent, and/or an anaesthetic agent.

According to the present disclosure, a bioadhesive formulation is provided. The bioadhesive formulation comprises a polycaprolactone dendrimer having a dendrimer core and a plurality of polycaprolactone chains extending from the dendrimer core, wherein at least one of the polycaprolactone chains has an end which is covalently attached with a diazirine, and wherein the diazirine converts to a carbene or a diazoalkyl when a stimulant is applied to the bioadhesive formulation. Methods of forming the bioadhesive formulation are also provided. The bioadhesive could be used in (i) the prevention of thrombosis from tissue fixation and/or (ii) the relief of discomfort and/or pain during and/or after surgery. Preferably, the bioadhesive formulation further comprises a hygroscopic additive, an antithrombotic agent, and/or an anaesthetic agent.

A nanoglue is formed with one or more bioadhesive polymers, one or more dendrimers, and optionally one or more therapeutic, prophylactic, or diagnostic agents. The bioadhesive polymers and dendrimers are modified with functional groups to permit crosslinking upon one or more stimuli, e.g., ultraviolet irradiation, and form hydrogel in situ at tissue sites. In the repair of corneal wounds, the nanoglue leads to improved rate of healing with less scarring and less inflammation, compared to non-treated cornea or ones treated with sutures. Therapeutic agents can be covalently conjugated to the precursor components and be delivered to specific eye compartments, providing a more efficacious treatment formulation of ocular disorders than delivering drugs in their free forms. Methods of making and using the hydrogel and hydrogel precursor compositions are also provided.

A nanoglue is formed with one or more bioadhesive polymers, one or more dendrimers, and optionally one or more therapeutic, prophylactic, or diagnostic agents. The bioadhesive polymers and dendrimers are modified with functional groups to permit crosslinking upon one or more stimuli, e.g., ultraviolet irradiation, and form hydrogel in situ at tissue sites. In the repair of corneal wounds, the nanoglue leads to improved rate of healing with less scarring and less inflammation, compared to non-treated cornea or ones treated with sutures. Therapeutic agents can be covalently conjugated to the precursor components and be delivered to specific eye compartments, providing a more efficacious treatment formulation of ocular disorders than delivering drugs in their free forms. Methods of making and using the hydrogel and hydrogel precursor compositions are also provided.

The invention relates to a multilayer structure comprising at least one layer of supramolecular material and one layer of rigid material, to a method for producing such a structure by casting a composition comprising a precursor of the supramolecular material, and to the uses of the structures produced, especially for applications where a dampening of impacts, vibrations and/or sound waves is desired, for example for producing locomotion vehicles such as automotive, rail, nautical, aeronautical or aerospace vehicles, or for the construction industry.

Adhesive damping systems are described. A damping system for reducing the effects on a substrate caused by a disruption in the substrate environment includes an adhesive having a plurality of three-dimensional particles dispersed therein. The particles are configured to provide a controlled response to an applied force field. The system further includes a sensor which measures an amplitude and frequency spectrum of the disruption. In a use configuration, the sensor determines the amplitude and frequency spectrum of the disruption received by the substrate; and the applied force field is dependent on the amplitude and frequency spectrum of the disruption.